Anika/Staar Staarvisc II
This article was originally published in The Gray Sheet
Sodium hyaluronate viscoelastic device gains FDA approval for use as an ophthalmic surgical aid via premarket approval application, announced April 27. The clear, viscous, injectable substance is used to protect delicate tissues inside the eye during ophthalmic surgeries like cataract removal and intraocular lens implantation. Staar Surgical has licensed the right to sell Staarvisc II from manufacturer Anika Therapeutics, and will offer it as part of a complete package for physicians to use for cataract procedures. Staar's original Staarvisc was approved by FDA in July 1999 (1"The Gray Sheet" July 12, 1999, p. 10)
You may also be interested in...
Staar Surgical's U.S. launch of Staarvisc viscoelastic solution will follow production ramp-up occurring over the next few months, the firm said following receipt of FDA approval July 7.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.